- A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer — Active Not Recruiting • Phase I • Oncology • NCT02123758.
- This study tested whether a new prostate cancer drug (ARN-509) can be safely combined with abiraterone acetate, and whether dose adjustments are needed.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this study is to investigate potential drug-drug interaction (DDI) between JNJ-56021927 and abiraterone acetate and between JNJ-56021927 and prednisone, determine safety of the combination and evaluate in a descriptive manner the efficacy in these participants. It will also, potentially provide dosing recommendations for abiraterone acetate in future studies when combined with JNJ-56021927. Conditions: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer Interventions: Abiraterone Acetate, Prednisone, JNJ-56021927 Lead Sponsor: Aragon Pharmaceuticals, Inc. Planned Enrollment: 57 participants